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Abstract
Ventilator-associated pneumonia is an important healthcare-associated infection. Interventions for the prevention of
ventilator-associated pneumonia are often used within bundles of care. Recent evidence has challenged widespread
practices mandating a review of subject. This article outlines guidance for ventilator-associated pneumonia prevention.
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Introduction
Ventilator-associated pneumonia (VAP) is a common
healthcare-associated infection (HCAI) occurring in
10–20% of patients mechanically ventilated in the
ICU.1,2 Although the exact attributable mortality
has proved difficult to define, it has significant conse-
quences with increased mortality, the length of ICU
stay and hospital stay and an increase in healthcare
costs.3–5 Furthermore, within a global setting of wor-
sening antimicrobial resistance, the treatment of
respiratory tract infections represents a significant
burden of antimicrobials in the ICU.
VAP occurs because the obtunded, endotracheally
intubated patient is at risk of inoculation of the lower
respiratory tract with microorganisms. The source of
the potential inoculate includes the oropharynx, sub-
glottic area, sinuses and gastrointestinal (GI) tract.
Access to the lower respiratory tract occurs around
the endotracheal tube (ETT) cuff.6 Interventions to
prevent VAP aim either to prevent repeated micro-
aspiration, colonisation of upper airway and GI
tract with potentially pathogenic organisms, or con-
tamination of ventilator/respiratory equipment.
Bundles of care are evidenced-based practices that
are grouped together to encourage the consistent
delivery of these practices. These bundles are
common in the ICU and have been developed for
the prevention of VAP.7,8 Recent evidence has
challenged current widespread practice and so up to
date recommendations on interventions for the pre-
vention of VAP are needed.
Recommended bundle of interventions
for the prevention of VAP
Elevation of head of bed (30–45)
Aspiration of oropharyngeal or gastric contents is
implicated in the pathogenesis of VAP.9 Nursing the
mechanically ventilated patient in a semi-recumbent
position aims to prevent aspiration of gastric content.
In an observational study in which aspiration wasmea-
sured using technectium (Tc)-99m labelled sulphur col-
loid placed into the stomach, patients who were nursed
supine in comparison to those nursed at 45, had sig-
nificantly more evidence of aspiration.10 In a rando-
mised trial, 90 patients were either nursed in a supine
position or at 45.11 Although the primary endpoint
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was clinically diagnosed VAP, which is highly vulner-
able to bias in an unblinded trial, there were significant
reductions in clinically and microbiologically diag-
nosed VAP (76% and 78% reductions respectively).
It is, however, unusual for patients to be nursed in a
fully supine position, therefore in a further randomised
trial patients were nursed at either 10 (supine) or 45
(semi-recumbent).12 The primary endpoint was the
incidence of VAP, defined by a rigorous criteria
based on culture of bronchoalveolar lavage (BAL)
fluid. Compliance with the correct degree of elevation
was poor, particularly in the semi-recumbent group.
Supine patients were elevated at 14.8  7.1 and
semi-recumbent patients at 26.5  8.2 by day 7.
There was no significant difference in the occurrence
of VAP between the two groups.
In summary, VAP is associated with nursing the
patient in a supine position. While elevating the bed
to 45 has been shown to reduce VAP, practically this
does not appear to be achievable. The exact degree of
elevation needed to prevent VAP is unclear but
aiming to avoid the supine position and raising the
bed to at least 30 is recommended.
Daily sedation interruption and assessment of
readiness to extubate
Sedation of endotracheally intubated patients is uni-
versal to ensure patient comfort. Continuous sedation
can lead to accumulation of sedatives and over-
sedation, and is associated with increased duration of
mechanical ventilation.13 Since intubation and mech-
anical ventilation predisposes patients to VAP, redu-
cing the duration of mechanical ventilation should
reduce that time at risk for developing VAP. Two stra-
tegies that have been used to reduce the duration of
mechanical ventilation are daily sedation interruption
(DSI) and daily spontaneous breathing trials (SBT).
In a trial of 128 patients randomised to either DSI
to the point of awakening or standard care (in which
sedation was managed according to clinical discre-
tion), the median duration of mechanical ventilation
was significantly lower in patients with DSI (4.9 vs.
7.3 days, p¼ 0.004).14 Furthermore, the ICU length of
stay was shorter for the intervention group (6.4 vs. 9.9
days, p¼ 0.02). In contrast, another trial compared
DSI in the context of a protocolised regimen of indi-
vidualised sedation. Patients were randomised to pro-
tocolised sedation plus DSI or only protocolised
sedation.15 There was no significant difference
between the two groups in time to extubation, dur-
ation of the ICU stay or duration of the hospital stay.
In a recent meta-analysis of DSI, there was insuffi-
cient evidence of benefit in terms of duration of mech-
anical ventilation, mortality or length of the ICU or
hospital stay.16 The authors advised caution in inter-
preting these results as negative for DSI, since the
trend is towards a reduction in these outcomes but
with wide confidence intervals.
In a trial combining DSI with SBT, in comparison
with standard sedation practice and SBT, patients in
the intervention arm had more days without mechan-
ical ventilation at 28 days (14.7 vs. 11.6 days) and
shorter duration of the ICU length of stay (median
9.1 vs. 12.9 days) and hospital stay (median 14.9 vs.
19.2 days).17
The protocolised approach to judging when a
patient is ready to wean and ultimately to tolerate
extubation has been the subject of meta-analysis.
Blackwood et al.18 examined trials that compared
weaning protocol interventions to standard care.
Protocolised weaning was associated with a 25%
(95% CI 9–39%) reduction in the mean duration of
mechanical ventilation.
Trials of sedation and weaning protocols predom-
inantly focus on duration of the mechanical ventila-
tion and ICU stay. In a prospective before-after study
of a nurse-led sedation protocol, there were signifi-
cantly fewer episodes of VAP amongst patients with
the nurse-led protocol (6% vs. 15%).19 Furthermore
in another non-randomised, before-after study of an
intervention of spontaneous awakening trials and
SBT to determine the preventability of ventilator-
associated events (VAE), spontaneous awakening
trials and SBT were associated with a significant
reduction in duration of mechanical ventilation and
a reduction in VAE risk per episode of mechanical
ventilation (odds ratio (OR) 0.63, 95% CI 0.42–
0.97) and infection-related ventilator-associated com-
plications (OR 0.35, 95% CI 0.17–0.71).20 Although
this study determines the preventability of a clinical
entity that does not solely represent VAP, it further
highlights that reducing time on mechanical ventila-
tion limits the time that the patient is at risk of its
complications.
In conclusion, there is sufficient evidence to sup-
port a strategy of DSI to prevent over-sedation and
liberation from mechanical ventilation through SBT.
Use of subglottic secretion drainage
Secretions are potentially able to bypass the ETT cuff,
especially when it is deflated. Secretions that pool
above the ETT but below the vocal cords are a poten-
tial source of pathogens that could cause VAP. Since
conventional suction methods cannot access this area,
ETT tubes that have a designated suction catheter for
this space allows this pool to be drained.
The benefits of subglottic secretion drainage (SSD)
have been analysed in three meta-analyses with a con-
sistent signal of a reduction in VAP. Dezflulian et al.
demonstrated a relative risk reduction of 0.51 (95%
CI 0.37–0.71) and excluding one trial that was the
predominant source of heterogeneity, SSD reduced
the duration of mechanical ventilation by 2 days
(95% CI 1.7–2.3) and length of the ICU stay by
3 days (95% CI 2.1–3.9).21 The reduction in VAP
was also demonstrated in another meta-analysis with
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a relative risk reduction of 0.56 (95% CI 0.45–0.69)
with an effect that reduced early-VAP but not late-
VAP.22 In a further meta-analysis of 13 RCTs with no
heterogeneity (I2 0%), the risk ratio for VAP was 0.55
(95% CI 0.46–0.66) for SSD.23 This meta-analysis
also found a reduced length of the ICU stay of 1.52
days (95% CI –2.94 – 0.11). In a recent RCT per-
formed subsequent to the meta-analyses, SSD was
associated with not only a reduction in microbiologic-
ally confirmed VAP but also a reduction in the per-
centage of days in the ICU on antibiotic therapy.24
SSD remains an intervention for the prevention of
VAP with a consistent signal of reducing VAP rates
and is therefore recommended in this bundle.
Avoidance of scheduled ventilator circuit changes
Humidified gases condense in the ventilator circuitry
and are at risk of becoming contaminated. Frequent
changes of the circuit is a risk factor for the develop-
ment of VAP.25 This may be due to the increased
manipulation of the ventilator tubing causing con-
taminated secretions to enter the bronchial tree via
the ETT lumen. Several studies have aimed to deter-
mine the optimum interval at which tubing should be
changed. In an observational study of separate peri-
ods of circuit changes every 2 days, 7 days or 30 days,
the highest VAP rate occurred at 2 days and the
lowest at 7 days.26 In two RCTs, one using heat
humidification27 and another using heat moisture
exchange filters,28 routine 7-day circuit changes were
compared to no routine changes, in which circuits
were changed at the clinicians discretion if faulty or
visibly soiled. There were no significant differences in
VAP between the two-trial arms in either trial. The
cost implications were significant, with 247 circuit
changes occurring in the 7-day group at a cost of
$7410 in comparison to 11 circuit changes in the
group with no routine changes, at a cost of $330.27
The evidence suggests that frequent circuit changes
are associated with an increased incidence of VAP,
probably due to the excessive manipulation of the
ventilator circuit. Changing the ventilator circuit
only when clinically indicated such as visible soiling
or when faulty, does not increase the incidence of
VAP and would result in significant cost savings com-
pared to routine changing of circuit.
Discussion
The diagnosis of VAP remains a challenge with a wide
range of diagnostic criteria used. The evidence con-
sidered for these recommendations includes studies
with differing diagnostic criteria for VAP. It is
beyond the scope of this work to grade the quality
of the evidence in this very broad area of interven-
tions. Furthermore, the range of methods used to
diagnose VAP in the UK ICUs varies widely.29 The
method of respiratory sampling can influence the rate
of VAP within an ICU, with a diagnostic strategy
based on clinical judgement and endotracheal aspirate
being associated with an over-diagnosis of VAP in
comparison to a strategy based on BAL sampling.30
This has significant implications for antibiotic therapy
and efforts to improve antibiotic stewardship in a time
of growing concern over antimicrobial resistance.
Recent evidence has called into question the wide-
spread use of oral chlorhexidine to decontaminate the
oropharynx. Oral chlorhexidine use has been asso-
ciated with a reduction in respiratory tract infections
in the ICU in high profile meta-analyses.31,32 These
meta-analyses included RCTs in both cardiac surgery
and general ICU patients, and are heavily influenced
by large trials that show benefit in cardiac surgery
patients.33–35 In a meta-analysis by Klompas et al.,36
cardiac surgery patients accounted for 51% of
patients. In non-cardiac patients, the reduction in
VAP was not significant with a relative risk of 0.78
(95% CI 0.60–1.02). Analysis of mortality endpoints
demonstrated a non-significant trend towards an
increase in mortality with chlorhexidine use in non-
cardiac surgery patients with a relative risk of 1.13
(95% CI 0.99–1.29). In another recent meta-analysis,
three strategies of decontamination, selective decon-
tamination of the digestive tract, selective oral decon-
tamination and oral decontamination with
chlorhexidine, were analysed for mortality endpoints
in general ICU patients.37 Decontamination with oral
chlorhexidine was associated with an increase in mor-
tality with an odds ratio of 1.25 (95% CI 1.05–1.50).
The reason for the possible increase in mortality is
unclear.
In light of this recent evidence, the ICS does not
recommend the use of oral chlorhexidine in non-car-
diac surgery patients. Furthermore, the National
Institute for Health and Care Excellence (NICE) has
recently withdrawn its VAP prevention recommenda-
tions in light of this new evidence.7
There is a paucity of evidence on outcomes for
tooth brushing alone, since many studies have been
performed in the context of chlorhexidine use as
standard care.38 Oral hygiene remains important in
ventilated patients in order to remove dental plaque
(which may lead to gingivitis or dental caries), for
patient comfort, and to promote a ‘normal’ microbial
community. Oral hygiene should continue to be pro-
vided despite stopping using chlorhexidine. Concerns
exist that toothbrushing could lead to both transient
bacteraemia and aspiration. Bacteraemia occurred in
23% of 98 individuals in an observational study,39
and 93% of these resolved within 20min of tooth-
brushing. While toothbrushing in the ICU patients
is under-researched, there is no clear signal of adverse
outcome from toothbrushing.38 In the absence of a
clear evidence base for optimal oral care, removal of
dental plaque and other debris from teeth, tongue and
oral mucosa with a foam swab or a toothbrush
appears unlikely to be harmful. Pragmatically,
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minimising the amount of water on the brush or swab
may reduce the volume of any material aspirated.
Gastrointestinal stress ulcer prophylaxis (SUP) has
been included in other VAP bundles.7,8 Raising the pH
of the stomach contents promotes colonisation with
potentially pathogenic organisms and so SUP remains
a balance of risk between GI bleeding and developing
VAP. Clinically important bleeding has been demon-
strated to occur in 1.5% of patients, with risk factors
identified as respiratory failure and coagulopathy.40
There is a suggestion that the rate of GI bleeding
has fallen in recent years with changing ICU prac-
tices.41 In a meta-analysis that aimed to determine
the effects of enteral feeding on SUP, the enterally
fed subgroup did not have a significant benefit in redu-
cing GI bleeding (OR 1.26, 95% CI 0.42–3.7) and fur-
thermore there was in increased risk of developing
VAP (OR 2.81, 95% CI 1.20–6.56).42 In an observa-
tional study of two 15-month periods during which
SUP was used in only one, there was no significant
difference in GI bleeding, VAP or mortality.43
Despite the low incidence of GI bleeding, proton
pump inhibitors (PPI) are widely used.44 Meta-
analysis of PPI in comparison to histamine H2 recep-
tor blockers (H2RB) has not demonstrated a
difference in terms of reduction in GI bleeding.45 In
a large pharmacoepidemiological observational study
of 35,312 mechanically ventilated patients receiving
PPI or H2RB, PPI use was associated with more GI
bleeding compared to H2RB (5.9% vs. 2.1%), more
VAP (38.6% vs. 27%) and more Clostridium difficile
(3.8% vs. 2.2%).46
There is insufficient evidence to give a clear recom-
mendation of the use of SUP and the potential pro-
tective benefits of enteral feeding. We therefore
recommend consideration of the risk profile of GI
bleeding in each patient with judicious use of SUP
in patients considered to be at risk of GI bleeding.
Summary
This bundle of interventions for the prevention of
VAP aims to highlight interventions, which if imple-
mented consistently, could reduce VAP rates.
Importantly this update does not recommend the
use of oral chlorhexidine outside of cardiac surgery
patients. The change in the use of oral chlorhexidine
should act as a word of caution that these recommen-
dations are bounded by current evidence and best
practice at the time of writing and so will be subject
to change as further developments are made in
this field.
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